AstraZeneca plc (AZN) Earns Hold Rating from Shore Capital
A number of other research firms have also recently issued reports on AZN. JPMorgan Chase & Co. restated a neutral rating and set a GBX 4,900 ($63.96) price target (up from GBX 4,800 ($62.66)) on shares of AstraZeneca plc in a report on Monday, August 8th. Deutsche Bank AG restated a buy rating and set a GBX 5,800 ($75.71) price target on shares of AstraZeneca plc in a report on Monday, August 8th. Jefferies Group set a GBX 5,400 ($70.49) price target on AstraZeneca plc and gave the stock a neutral rating in a report on Monday, August 8th. Goldman Sachs Group Inc. set a GBX 4,000 ($52.21) price target on AstraZeneca plc and gave the stock a sell rating in a report on Wednesday, August 10th. Finally, Beaufort Securities restated a hold rating on shares of AstraZeneca plc in a report on Wednesday, August 10th. Five investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. AstraZeneca plc currently has an average rating of Hold and a consensus price target of GBX 4,926.80 ($64.31).
AstraZeneca plc (LON:AZN) opened at 5048.00 on Wednesday. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00. The company’s market capitalization is GBX 63.86 billion. The company has a 50 day moving average of GBX 5,015.00 and a 200 day moving average of GBX 4,398.79.
The company also recently disclosed a dividend, which was paid on Monday, September 12th. Investors of record on Thursday, August 11th were issued a dividend of GBX 68.70 ($0.90) per share. The ex-dividend date of this dividend was Thursday, August 11th. This represents a dividend yield of 1.37%.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.